1. Protecting participants in bioequivalence studies for abbreviated new drug applications during the COVID-19 public health emergency Publication: [Silver Spring, MD] : Center for Drug Evaluation and Research, January 2021 Subject(s): Drug ApprovalPatient SafetyTherapeutic EquivalencyCOVID-19United StatesUnited States. Department of Health and Human ServicesUnited States. Food and Drug Administration